Activated PAR-2 Regulates Pancreatic Cancer Progression through ILK/HIF-α–Induced TGF-α Expression and MEK/VEGF-A–Mediated Angiogenesis  by Chang, Li-Hsun et al.
The American Journal of Pathology, Vol. 183, No. 2, August 2013ajp.amjpathol.orgTUMORIGENESIS AND NEOPLASTIC PROGRESSION
Activated PAR-2 Regulates Pancreatic Cancer Progression
through ILK/HIF-aeInduced TGF-a Expression and
MEK/VEGF-AeMediated Angiogenesis
Li-Hsun Chang,* Shiow-Lin Pan,y Chin-Yu Lai,* An-Chi Tsai,z and Che-Ming Teng*From the Pharmacological Institute,* College of Medicine, National Taiwan University, Taipei; the Ph.D. Program for Cancer Biology and Drug Discovery,y
College of Medical Science and Technology, Taipei Medical University, Taipei; and the Institute of Biotechnology and Pharmaceutical Research,z National
Health Research Institutes, Zhunan, TaiwanAccepted for publicationC
P
hApril 8, 2013.
Address correspondence to
Che-Ming Teng, Ph.D., Phar-
macological Institute, College
of Medicine, National Taiwan
University, No. 1, Jen-Ai Road,
Section 1, Taipei 100, Taiwan.
E-mail: cmteng@ntu.edu.tw.opyright ª 2013 American Society for Inve
ublished by Elsevier Inc. All rights reserved
ttp://dx.doi.org/10.1016/j.ajpath.2013.04.022Tissue factor initiates the process of thrombosis and activates cell signaling through protease-activated
receptor-2 (PAR-2). The aim of this study was to investigate the pathological role of PAR-2 signaling in
pancreatic cancer. We ﬁrst demonstrated that activated PAR-2 up-regulated the protein expression of
both hypoxia-inducible factor-1a (HIF-1a) and HIF-2a, resulting in enhanced transcription of trans-
forming growth factor-a (TGF-a). Down-regulation of HIFs-a by siRNA or YC-1, an HIF inhibitor, resulted
in depleted levels of TGF-a protein. Furthermore, PAR-2, through integrin-linked kinase (ILK) signaling,
including the p-AKT, promoted HIF protein expression. Diminishing ILK by siRNA decreased the levels of
PAR-2einduced p-AKT, HIFs-a, and TGF-a; our results suggest that ILK is involved in the PAR-2e
mediated TGF-a via an HIF-aedependent pathway. Furthermore, the culture medium from PAR-2e
treated pancreatic cancer cells enhanced human umbilical vein endothelial cell proliferation and tube
formation, which was blocked by the MEK inhibitor, PD98059. We also found that activated PAR-2
enhanced tumor angiogenesis through the release of vascular endothelial growth factor-A (VEGF-A)
from cancer cells, independent of the ILK/HIFs-a pathways. Consistent with microarray analysis, acti-
vated PAR-2 induced TGF-A and VEGF-A gene expression. In conclusion, the activation of PAR-2 signaling
induced human pancreatic cancer progression through the induction of TGF-a expression by ILK/HIFs-a,
as well as through MEK/VEGF-Aemediated angiogenesis, and it plays a role in the interaction between
cancer progression and cancer-related thrombosis. (Am J Pathol 2013, 183: 566e575; http://dx.doi.org/
10.1016/j.ajpath.2013.04.022)Supported by the National Science Council of the Republic of China and
National Science Council (Taiwan) grant 99-2628-B-002-024-MY3.
Current address of A.-C.T., School of Pharmacy, College of Pharmacy,
Taipei Medical University, Taipei, Taiwan.The association between thrombosis and malignancies is
known as Trousseau syndrome, and advanced pancreatic
cancer has been associated with venous thromboembolism in
epidemiological studies. The up-regulation of tissue factor
(TF), the primary initiator of coagulation, is considered
a biomarker for the development of thrombosis and cancer
progression. TF overexpression can result from the mutation
of oncogenes, such asKRAS and p53, and it is associated with
tumor progression and angiogenesis in colorectal cancer. The
expression of TF has also been related to staging, overall
survival, microvessel density, metastasis, and the rate of
thrombosis of patientswith cancer. TF functions by binding to
factor VII (FVII), leading to the activation of the coagulation
cascade and protease-activated receptor (PAR)-2 signalingstigative Pathology.
.and integrin ligation, which inﬂuence cancer progression,
such as cell survival, angiogenesis, and invasion.1
The PARs are members of the GPCR family, and they
are activated by different proteases, including thrombin,
trypsin, and coagulant factors. PAR-1, PAR-3, and PAR-4 are
thrombin-activated receptors, whereas PAR-2 is activated by
trypsin. This diversity allows PARs to act in a broad spectrum
of pathological capacities in different diseases, including
cancers,2 such as colorectal3 and pancreatic4 cancers. The
PAR-2 in Pancreatic Cancer Progressionactivation of PAR-2 has been shown to increase tumor cell
proliferation and invasion via mitogen-activated protein
kinase (MAPK) activation, and to stimulate angiogenesis by
releasing vascular endothelial growth factor-A (VEGF-A).5,6
Furthermore, under hypoxic conditions, tumor cells release
microvesicles containing TF, which activates PAR-2 sig-
naling in endothelial cells (ECs) and subsequently induces
angiogenesis.7 These ﬁndings demonstrate that TF/FVII/
PAR-2 signaling promotes tumor angiogenesis through the
release of VEGF from tumors and the activation of ECs by
PAR-2.
Integrin-linked kinase (ILK) is an integrin-interacting
protein that possesses both serine/threonine protein kinase
activity and adaptor properties. The interaction of ILK with
the cytoplasmic tail of b1 integrin, which is ligated with TF
and PAR-2, induces survival signaling through the phos-
phorylation of AKT (Ser-473) and glycogen synthetase
kinase (GSK)-3b (Ser-9).8 Several studies have indicated
that ILK is overexpressed in various types of cancers and is
correlated with a poor patient prognosis.9 ILK also increases
hypoxia-inducible factor (HIF)-1a accumulation by acti-
vating the AKT/mammalian target of rapamycin pathway
and inducing transcription of VEGF-A, which plays a role in
regulating angiogenesis.10 Moreover, a recent study showed
that ILK interacts with centrosomal proteins and causes
mitotic spindle reorganization.11 As a result, ILK regulates
cancer progression through its effects on integrin signaling
and its actions as a mitotic regulator.
The HIFs are hallmarks of the hypoxic tumor microenvi-
ronment. There are two subunits of HIFs: O2-sensing a-sub-
units (HIF-1a, HIF-2a, and HIF-3a) and a stable b-subunit
(HIF-1b). In many human cancers, both HIF-1a and HIF-2a
are correlated with angiogenesis and poor patient prognosis,
but they function through different mechanisms to regulate
tumor growth. However, the role of HIF-3a remains unclear.
Several studies have shown that HIF-1a, but not HIF-2a,
enhances the transcription of glycolytic pathway genes to raise
energy uptake. In contrast, HIF-2a, which is highly expressed
in tumor-initiating and stem cellelike cells, acts to directly
increase the activity of octamer-binding transcription factor 4,
which maintains stem cells in an undifferentiated state. The
switch in the expression of HIFs may affect cancer progression
and angiogenesis because of the involvement of HIF-1a and
HIF-2a in different stages of tumor progression and vascular
development. Therefore, targeting of HIFs is an important
potential therapeutic method in solid tumors.12e14
The tumor microenvironment is capable of inducing
growth factor expression and survival signals through the
AKT/mammalian target of rapamycin and Ras/Raf/MEK/
extracellular signaleregulated kinase (ERK) pathways. This
results in cancer cell growth and the expression of angiogenic
factors that control the tumor angiogenic switch, including
VEGF-A, ﬁbroblast growth factor, platelet-derived growth
factor, and insulin-like growth factor. Increased tumor-
associated angiogenesis also results in improved tumor
growth and metastasis. Therefore, the disruption ofThe American Journal of Pathology - ajp.amjpathol.orgcommunication between cancer cells and the tumor micro-
environment is a viable therapeutic strategy to target
angiogenesis.15
PAR-2 has previously been reported to be associated with
cell proliferation and cyclooxygenase-2 expression in
pancreatic cancer cells.4 In one of our previous studies, we
found that PAR-1 activation had an effect on the accumulation
of HIF-1a and twist protein, which acts to regulate cell
motility.16 Therefore, we interestingly investigated if PAR-2
activation may have some pathological effects on pancreatic
cancer. We report that the activation of PAR-2 causes an
increase in HIF-aeregulated transforming growth factor
(TGF)-a expression via ILK signaling, as well as enhanced
angiogenesis viaMEK-ERKemediatedVEGF-A expression.
Materials and Methods
Cell Culture
Human pancreatic cancer cell lines AsPC-1 and BxPC-3,
human colorectal cancer cell line HCT-116, and human
umbilical vein endothelial cells (HUVECs) were purchased
from Bioresource Collection and Research Center (Hsinchu,
Taiwan). Human pancreatic and colorectal cancer cells were
cultured in RPMI 1640 medium with 10% fetal bovine serum
(v/v). HUVECs were maintained in M199 contained with
20% fetal bovine serum (v/v). Both media were supple-
mented with 100 U/mL penicillin, 100 mg/mL streptomycin,
and 2.5 mg/mL amphotericin B. Cells were maintained in
a humidiﬁed incubator at 37C in 5% CO2/95% air.
Reagents
RPMI 1640 medium, M199 medium, fetal bovine serum,
penicillin, streptomycin, and all other tissue culture reagents
were obtained from GIBCO/BRL Life Technologies (Grand
Island, NY). LY294002, PD98059, SB203580, SP600125,
and nucleolin antibody were ordered from Sigma Chemical
(St. Louis, MO). CoCl2 was purchased from Wako (Osaka,
Japan). PAR-2eactivating peptide (PAR-2 AP), SLIGKV-
NH2, was ordered from Bachem (Bubendorf, Switzerland).
TRIzol reagent was from Invitrogen (Carlsbad, CA),
random primer and M-MLV RT were purchased from
Promega (Madison, WI), and pro-Teq was from Protech
(Taipei, Taiwan). Antibodies against HIF-1a and Matrigel
basement membrane matrix were purchased from BD
Biosciences (San Jose, CA). Phosphorylated (Ser-473) AKT
was bought from Epitomics (Burlingame, CA). Antibodies
speciﬁc for total AKT, phosphorylated (Ser-9) or total GSK-
3b, phosphorylated (Thr-202/Tyr-204) or total p44/p42
MAPK, ILK, pro-TGF-a, and HIF-2a antibodies were ob-
tained from Cell Signaling Technology (Beverly, MA).
Actin antibody was purchased from Chemicon (Billerica,
MA). Antibodies to horseradish peroxidaseeconjugated
anti-mouse and anti-rabbit IgGs were ordered from Santa
Cruz Biotechnology (Santa Cruz, CA).567
Chang et alMicroarray Analysis
BxPC-3 cells were treated with or without PAR-2 AP for 4
hours. Total RNAs were harvested by TRIzol reagent, fol-
lowed by puriﬁcation using an RNeasy Mini kit (Qiagen,
Valencia, CA). Samples were processed and performed
according to the procedure of Human OneArray from
Phalanx Biotech (Hsinchu). The results were analyzed by the
Rosetta Resolver System (Rosetta Biosoftware, Seattle,
WA). Compared with the control sample, the fold change of
gene expression is duplicated and established at log2 jfold
changej  0.5 and P< 0.05, by using DAVID Bioinformatic
Resources (NIH, Bethesda, MD) subjected to pathway and
gene ontology analysis. Microarray data is has been uploa-
ded to the Gene Expression Omnibus (http://www.ncbi.nlm.
nih.gov/geo; accession number GSE44827).
RT-PCR Data
Total RNA was isolated with TRIzol reagent by a standard
protocol. mRNA (5 mg) was incubated with random primer
at 65C for 5 minutes, and then reacted with M-MLV RT at
37C for 1 hour to obtain cDNA. The primer sets were as
follows: TF, 50-CTACTGTTTCAGTGTTCAAGCAGTGA-30
and 50-CAGTGCAATATAGCATTTGCAGTAGC-30; PAR-
2, 50-TGCTGGGGGCCGCCATCCTGCTA-30 and 50-ATA-
GGCAATCTTCAAGGGGAACC-30; VEGF-A, 50-GAAGT-
GGTGAAGTTCATGGATGTC-30 and 50-CGATCGTTCT-
GTATCAGTCTTTCC-30; TGF-a, 50-TCGCTCTGGGTATT-
GTGTTG-50 and 50-GACCTGGCAGCAGTGTATCA-30; and
actin, 50-GGTGGCTTTTAGGATGGCAAG-30 and 50-ACT-
GGAACGGTGAAGGTGACAG-30. For TF and VEGF-A, a
PCR was performed with 30 cycles, with denaturation at 94C
for 45 seconds, annealing at 58C for 45 seconds, and ex-
tension at 72C for 45 seconds. For TGF-a and actin, 30 cycles
of ampliﬁcation were done under the following conditions:
94C for 20 seconds, 60C for 20 seconds, and 72C for 40
seconds. For PAR-2, the reaction condition was performedwith
30 cycles at 95C, 54C, and 72C for 30 minutes. The PCR
products were analyzed by electrophoresis on a 1.5% agarose
gel with ethidium bromide.
Western Blot Analysis
Whole cell lysate was extracted by radioimmunoprecipi-
tation assay buffer containing Tris (50 mmol/L), sodium
chloride (150 mmol/L), SDS (0.1%), sodium deoxycholate
(0.5%), and NP-40 (1%). Nuclear extraction and Western
blot analysis were used as described previously.16
Transient Transfection
We used validated siRNA directed against HIF-1a, HIF-2a,
and ILK mRNA from Ambion (Carlsbad). BxPC-3 cells were
trypsinized and 106 cells were counted into 100 mL of
Nucleofector Solution (Amaxa/Lonza, Allendale, NJ) with568100 nmol/L siRNA. Transfection was performed using
Nucleofector II (Amaxa/Lonza), according to the manufac-
turer’s instructions. The transfected cells were seeded into 6-
well plates for 48 hours and then prepared for further analysis.
VEGF-A ELISA
AsPC-1, BxPC-3, and HCT-116 cells were seeded as 150,000
cells per well into a 24-well plate for overnight analysis. Cells
were treated with the indicated concentration of FVIIa or
PAR-2 AP for 24 hours, and then the culture medium was
collected. The amount of VEGF-A in culture medium was
detected by a Human VEGF-A Quantikine ELISA (enzyme-
linked immunosorbent assay) Kit (R&D Systems, Minneap-
olis, MN), according to the manufacturer’s instructions.
HUVEC Proliferation Assay
For preparation of conditioned medium, BxPC-3 cells were
treated with or without PAR-2 AP for 24 hours, and then
conditioned medium was collected. HUVECs were seeded
as 5000 cells per well into a 96-well plate for overnight
analysis. After cells adhered, culture medium was replaced
by conditioned medium for 48 hours. HUVEC proliferation
was measured by 0.5% crystal violet with methanol (4:1).
Crystal violet was solubilized with 0.1 mol/L citric acid, and
absorbance was detected at a wavelength of 550 nm.
Tube Formation
A 96-well plate was coated with 60 mL Matrigel (BD
Bioscience) and incubated in 37C for 1 hour before starting to
subculture HUVECs. After subculturing and counting 20,000
HUVECs, cells were resuspended into conditioned medium
and seeded onto aMatrigel-coatedwell for 24 hours. Themean
of tube length was measured by ImageJ version 1.46r software
(NIH) in ﬁve areas randomly using a microscope.
Statistics
Every experiment was performed at least three times. All data
represent means SEM from three independent experiments.
Statistical analysis was performed using a Student’s t-test.
Results
PAR-2 AP Induces Gene Expression in
TF/PAR-2eExpressing BxPC-3 Cells
Many studies have demonstrated that the activation of TF/
PAR-2 signaling regulates tumor proliferation, angiogenesis,
and metastasis.1 In this study, we investigated the expression
of TF and PAR-2 in pancreatic cancer cell lines BxPC-3 and
AsPC-1, and we found that TF and PAR-2 mRNAs were
constitutively expressed in both cell lines (Figure 1A). Gene
proﬁling may be used as an approach to investigate the
different physiological and pathological roles of PAR-2ajp.amjpathol.org - The American Journal of Pathology
PAR-2 in Pancreatic Cancer Progressionsignaling, and microarray-based gene expression studies
have shown that PAR-2 regulates several genes in human
breast cancer cells and human kidney cells, including cyto-
kines, chemokines, and growth factors.17,18 Therefore, weThe American Journal of Pathology - ajp.amjpathol.orgexamined the proﬁle of genes expressed in response to PAR-2
AP in pancreatic cancer BxPC-3 cells by microarray analysis;
a cluster analysis of PAR-2 AP-regulated genes is shown in
Figure 1B. By using DAVID Bioinformatic Resources, we
found that PAR-2 AP-mediated genes can be overlaid on the
renal cell carcinoma pathway (Kyoto Encyclopedia of Genes
and Genomes hsa04960), which involves the deregulation of
multiple oncogenes. In particular, HIF, which is a major
transcription factor in renal cell carcinoma, inﬂuences cancer
progression owing to the absence of Von HippeleLindau
disease.19 Themicroarray results showed that PAR-2 induced
the up-regulation of HIF-aeactivated target genes, such as
glucose transporter 1 (GLUT1;SLC2A1),VEGF-A, andTGF-a;
however, HIF-2a (EPAS1) was down-regulated (Table 1). The
activation of MAPK signaling by PAR-2 subsequently targets
the AP-1 and Ets-1 transcription factor families. As shown in
Table 1, the expression of MAPK1, Ets-1, and c-Jun was
increased in BxPC-3 cells treated with PAR-2 AP, suggesting
that the activationof PAR-2 could regulateHIF-ae andMAPK-
mediated signaling in human pancreatic cancer cells.Activation of PAR-2 Increases the Expression of the
a Forms of HIFs, ProeTGF-a, and VEGF-A in Human
Pancreatic Cancer Cells
Previous studies have shown that the activation of PAR-1
increases HIF-1a protein levels in human colorectal cancer
cells.16 The results of this study suggest that the HIF pathway
is involved in PAR-2eactivated human pancreatic cancer
cell functions. Next, we proved that PAR-2 AP signiﬁcantly
induced HIF-1a and HIF-2a protein expression in a
concentration-dependent manner in BxPC-3 and AsPC-1
human pancreatic cancer cell lines (Figure 2, A and B). In
addition, HIF-1a protein expression was also up-regulated
by PAR-2 AP in human colorectal cancer HCT-116 cells
(Figure 2A). CoCl2 was used as a positive control. Further-
more, FVIIa-induced TF/FVII/PAR-2 signaling increased
HIF-1a and HIF-2a protein expression in both pancreatic
cancer cell lines (Figure 2C). These results indicate that
activation of PAR-2 can induce HIF-a protein accumulation
in human cancer cells under normoxic conditions.
To validate the results of our microarray analysis, we next
performed RT-PCR assays to conﬁrm the changes in TGF-a
and VEGF-A mRNA expression. The results showed that
PAR-2AP signiﬁcantly induced TGF-a andVEGF-AmRNAFigure 1 Hierarchical clustering of gene proﬁles in TF- and PAR-2e
expressing pancreatic cancer cell lines. A: RT-PCR analysis of TF- and PAR-2
mRNA levels. BxPC-3 and AsPC-1 were grown in the culture medium. B:
Clustering analysis of microarray data comparing BxPC-3 cells with those
treated with PAR-2 AP. Total RNA of BxPC-3 cells treated with or without
100 mmol/L PAR-2 AP for 4 hours was extracted and analyzed by Human
OneArray. Genes signiﬁcantly different, with P < 0.05 after the treatment,
were pooled and used to generate heat maps. Up-regulated and down-
regulated genes are represented in red and green, respectively. CTL,
control; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
569
Table 1 Renal Cell Carcinoma Pathway Genes (Kyoto Encyclopedia of Genes and Genomes hsa04960) Are Regulated by PAR-2 AP in BxPC-3
Cells
Accession no. Gene symbol Gene name Log2 (ratio) P value
NM_001430.4 EPAS1 Endothelial PAS domain protein 1 0.695304 0.000378
NM_005238.3* ETS1 V-ets erythroblastosis virus E26 oncogene homolog 1 (avian) 0.626951 0.014179
NM_002228.3 JUN Jun proto-oncogene 0.607265 0.00028
NM_002755.3 MAP2K1 Mitogen-activated protein kinase kinase 1 0.590325 0.004437
NM_003629.3y PIK3R3 Phosphoinositide-3-kinase, regulatory subunit 3 (g) 0.659642 0.005429
NM_002834.3 PTPN11 Protein tyrosine phosphatase, nonreceptor type 11 0.624667 0.000243
NM_006516.2 SLC2A1 Solute carrier family 2 (facilitated glucose transporter), member 1 0.54684 0.027656
NM_003236.2z TGFA Transforming growth factor a 0.510164 0.044585
NM_001171629.1x VEGFA Vascular endothelial growth factor A 0.514638 0.003685
BxPC-3 cells were treated with 100 mmol/L PAR-2 AP for 4 hours before total RNA was harvested for microarray analysis. Each unique splice variant of the
gene was also tested. Different accession numbers are given.
*ETS1: NM_005238.3, NM_001162422.1, and NM_001143820.1.
yPIK3R3: NM_003629.3 and NM_001114172.1.
zTGFA: NM_003236.2 and NM_001099691.1.
xVEGFA: NM_001171629.1, NM_001171626.1, NM_001171625.1, NM_001171624.1, NM_001171623.1, NM_001033756.2, NM_001025368.2,
NM_001025367.2, NM_003376.5, NM_001025366.2, NM_001171627.1, and NM_001025369.2.
PAS, PER-ARNT-SIM.
Chang et alexpression (Figure 2D), as well as proeTGF-a protein ex-
pression in human pancreatic cancer cells (Figure 2E).
In addition, PAR-2 AP caused AsPC-1, BxPC-3, and HCT-
116 cells to release VEGF-A into the culture medium in
a concentration-dependent manner (Figure 2F). Moreover,
activation of TF/FVII/PAR-2 induced similar effects in
pancreatic cancer cell lines, including increase of proeTGF-a
(Figure 2E) and VEGF-A (Figure 2G). Taken together, these
results suggest that PAR-2 signaling signiﬁcantly induces
the expression of HIF-a proteins, proeTGF-a protein, and
VEGF-A in human pancreatic cancer cells.
PAR-2 AP Induces HIF-aeMediated Production of
TGF-a But Not VEGF-A
Both TGF-a and VEGF-A are known to be target genes of
the transcription factors HIF-1a and HIF-2a.12 However, in
this study, a reduction in the expression levels of the HIF-a
proteins (HIF-1a and/or HIF-2a) in response to siRNA
treatment (Figure 3A) correlated with a decrease in proe
TGF-a protein expression (Figure 3B), but not VEGF-A
production (Figure 3C), after PAR-2 AP treatment. Inter-
estingly, a reduction in HIF-1a levels also resulted in
increased nuclear expression of HIF-2a, although siRNA
targeting of HIF-2a did not have an effect on the nuclear
localization of the HIF-1a protein (Figure 3A). This ﬁnding
indicates an unknown relationship between HIF-1a and HIF-
2a. In addition, we used a well-known HIF inhibitor, YC-1,
to investigate the relationship between HIFs and TGF-a. As
shown in Figure 3D, YC-1 reduced PAR-2 AP-induced
HIF-1a and HIF-2a protein expression in a concentration-
dependent manner, which directly correlated with the
observed TGF-a expression pattern in human pancreatic
BxPC3 cancer cells. Taken together, these data illustrate that
PAR-2 AP-mediated TGF-a production occurs via the HIFs
(HIF-1a and HIF-2a) signaling pathway.570PAR-2 Activation Regulates TGF-a Production through
ILK/HIF-a Signaling
Previous research has demonstrated that the HIF-1ae
VEGF-A pathway is regulated by ILK in prostate cancer.10
We ﬁrst determined that ILK protein is expressed in both
BxPC-3 and AsPC-1 pancreatic cancer cell lines (Figure 4A).
Once activated by integrin or growth factors, ILK is capable
of directly phosphorylating its downstream substrates,
including p-AKT (Ser-473) and p-GSK-3b (Ser-9). We
observed that PAR-2 AP up-regulated the protein expression
of p-AKT, p-GSK-3b, and p-ERK (Figure 4B). Although p-
ERK is not a substrate of ILK, it functions in a signaling
pathway downstream of activated PAR-2. Then, the down-
regulation of ILK by ILK-speciﬁc siRNA partially inhibi-
ted PAR-2 AP-mediated p-AKT expression, although it did
not effectively inhibit PAR-2 AP-induced p-GSK-3b or p-
ERK protein expression (Figure 4C). We, therefore, suggest
that PAR-2 AP-activated ILK signaling functions via p-AKT
to inﬂuence cellular phenotypes.
We further determined whether PAR-2 induced HIF-
mediated TGF-a production or the release of VEGF-A via
an ILK-dependent pathway. Our results demonstrated that an
siRNA-mediated decrease in ILK expression led to reduced
levels of both HIF-a and TGF-a proteins (Figure 4D), but it
did not attenuate the release of VEGF-A in BxPC-3 cells
(Figure 4E). Thus, we proved that ILK is involved in the
PAR-2emediated production of TGF-a via the HIF-ae
dependent pathway in human pancreatic cancer cells.
PAR-2 AP-Treated Conditioned Medium Enhances
HUVEC Proliferation and Tube Formation via an
MEK-Dependent Pathway
Our results showed that PAR-2einduced VEGF-A protein
was not regulated by ILK and HIF-a; however, previousajp.amjpathol.org - The American Journal of Pathology
Figure 2 PAR-2 AP increases the expression of
HIFs-a and their downstream target genes.
Nuclear extracts were subjected to immunoblot
with HIF-1ae and HIF-2aespeciﬁc antibodies.
The level of nucleolin protein in the lysates was
used as a loading control (CTL). A: BxPC-3, AsPC-
1, and HCT-116 cells were treated with PAR-2 AP
at the indicated concentrations or with 100 mmol/
L CoCl2 as a positive control for 4 hours. B: HIF-
2a, BxPC-3, and AsPC-1 were detected using cell
lines treated with PAR-2 AP at the indicated
concentrations or with 100 mmol/L CoCl2, as
a positive control, for 4 hours. C: BxPC-3 and
AsPC-1 cell lines were treated with FVIIa at the
indicated concentrations for 4 hours. D: BxPC-3
cells were treated with 100 mmol/L PAR-2 AP for
the indicated time interval before VEGF-A and TGF-
a mRNA levels were determined by RT-PCR anal-
ysis. E: BxPC-3 and AsPC-1 cells were treated with
PAR-2 AP or FVIIa at the indicated concentration
for 24 hours, and whole cell lysates were subjected
to immunoblot with antibodies against proeTGF-
a and actin. F: AsPC-1, BxPC-3, and HCT-116 cells
were treated with PAR-2 AP at the indicated
concentration. G: AsPC-1 and BxPC-3 cells were
treated with FVIIa at the indicated concentration.
After 24 hours, VEGF-A levels in the media were
determined using an ELISA kit. *P < 0.05.
PAR-2 in Pancreatic Cancer Progressionstudies have shown that PAR-2 regulates VEGF-A
expression through the MAPK pathway in human breast
cancer cells5 and human glioblastoma cells.6 We, there-
fore, examined whether the MAPK pathway is involved in
PAR-2 AP-regulated VEGF-A release in human pancreatic
cancer cells, and we found that the increase in VEGF-A
release in response to PAR-2 AP is inhibited by the
MEK inhibitor, PD98059 (Figure 5A). Because this
ﬁnding is consistent with results from our microarray
analysis, we suggest that PAR-2 AP triggers the MEK-Ets1
pathway and, thus, enhances VEGF-A transcription. We
also demonstrated that, in BxPC-3 and HCT-116 cells,
PAR-2 AP increases the release of VEGF-A into the
culture medium (Figure 2E).
Next, we investigated whether the PAR-2emediated
release of VEGF into a tumor-conditioned medium stimu-
lates ECs to proliferate and differentiate in an in vitro
angiogenesis model. As shown in Figure 5, B and C, PAR-2
AP-treated tumor-conditioned medium signiﬁcantly induced
HUVEC proliferation and enhanced tube formation, both of
which were attenuated by the conditioned medium con-
taining PD98059, an MEK inhibitor. Consequently, theseThe American Journal of Pathology - ajp.amjpathol.orgresults demonstrate that the activation of PAR-2 promotes
angiogenesis through MEK-mediated VEGF-A release.
Discussion
Cancer-related thrombosis is a well-known phenomenon
in patients with pancreatic cancer. TF is a key factor for
clotting, inﬂammation, tumor progression, and angiogen-
esis; the formation of a TF/VIIa complex results in the
cleavage of PAR-2, a GPCR, which then modulates cellular
functions, such as cell proliferation and survival. In human
pancreatic cancer cells, we found that activated PAR-2
induces ILK/HIF-a signaling, thus affecting TGF-a protein
expression and VEGF-A release, which ultimately leads
to the induction of angiogenesis via an MEK-dependent
pathway.
As previously mentioned, patients with pancreatic cancer
are at a high risk of developing venous thromboembolism.
Furthermore, previous research has indicated that the
expression of TF, including full-length TF and alternative-
splicing TF, is correlated with tumor progression, angio-
genesis, and prognosis.20e22 Herein, we examined the role571
Figure 3 Depletion of HIFs-a decreases PAR-2einduced HIF-a and TGF-a expression, but it does not inﬂuence VEGF release. BxPC-3 cells were transfected
with 200 nmol/L control siRNA (siCTL), siHIF-1a (siH1), or siHIF-2a (siH2) by using the Nucleofector device. A: BxPC-3 cells were treated with or without 100
mmol/L PAR-2 AP for 4 hours. Nuclear extracts were subjected to immunoblot analysis using speciﬁc antibodies for HIF-1a, HIF-2a, and nucleolin. B: BxPC-3
cells were treated with or without PAR-2 AP for 24 hours. Whole cell lysates were subjected to immunoblot with proeTGF-a and actin primary antibodies.
C: BxPC-3 cells were treated with or without PAR-2 AP for 24 hours before the culture media were collected and VEGF-A levels were detected by an ELISA kit.
D: BxPC-3 cells were pretreated with YC-1 at the indicated concentrations for 30 minutes before treatment with or without 100 mmol/L PAR-2 AP at the
indicated concentrations for 4 hours (top panel) or 24 hours (bottom panel). **P < 0.01.
Chang et alof PAR-2 in human pancreatic cancer by using PAR-2eAP-
SLIGKV-NH2, which can activate PAR-2 and trigger
signaling pathways by mimicking the action of trypsin.
Previous research has demonstrated that activated PAR-2
can inﬂuence many genes, including cell cycle regulator
and inﬂammatory mediators in human breast cancer MDA-
MB-231 cells17 and human HEK293 kidney cells.18 In the
present study, microarray analysis revealed that PAR-2 APFigure 4 ILK signaling participated in PAR-2emediated HIF-a and TGF-a regu
subjected to immunoblot analysis, as follows. A: BxPC-3 and AsPC-1 cells cultured
PAR-2 AP for different time intervals. C: BxPC-3 cells treated with or without 10
treated with or without 100 mmol/L PAR-2 AP for 4 hours (top panel) or whole ce
24 hours (bottom panel). E: VEGF-A levels in the culture medium from PAR-2 AP-tr
The p and t represent phosphorylated and total, respectively. The mean values
**P < 0.01. CTL, control.
572regulates genes encoding proteins involved in many bio-
logical functions, including the regulation of cell growth and
differentiation (MAPK family, such as JUN and MAP2K1)
and tumor progression (TGF-a and VEGF-A). Furthermore,
the resulting gene proﬁle could be linked with a renal
carcinoma pathway (Kyoto Encyclopedia of Genes and
Genomes hsa04960) (Table 1) that involves multiple genes
associated with the HIF pathway.lation, but not VEGF-A regulation. Whole cell lysate or nuclear extracts were
in the culture medium. B: BxPC-3 and AsPC-1 cells treated with 100 mmol/L
0 mmol/L PAR-2 AP for 10 minutes. D: Nuclear extracts from BxPC-3 cells
ll lysate from BxPC-3 cells treated with or without 100 mmol/L PAR-2 AP for
eated BxPC-3 cells collected after 24 hours, as measured using an ELISA kit.
of p-AKT fold change, normalized by t-AKT, were shown below the panel.
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Figure 5 VEGF-Aeregulated HUVEC growth and tube formation induced
by PAR-2 AP is disrupted by the MEK inhibitor, PD98059. A: BxPC-3 cells were
pretreated with 20 mmol/L PD98059 (PD) for 30 minutes, followed by 100
mmol/L PAR-2 AP for 24 hours. Culturemedia (CM)were collected fromBxPC-3
cells, and VEGF-A levels were determined using an ELISA kit. B: HUVECs were
treated with CM for 48 hours. Cells were stained with crystal violet, and cell
growth was determined by measuring absorbance at 550 nm. C: In vitro
Matrigel tube formation assay. Top panel: HUVECs were suspended in CM and
seeded onto Matrigel-coated wells for 24 hours. Images of tube formation are
shown. Bottom panel: The quantiﬁcation of tube formation was performed
using ImageJ software. Data represent means SEM from three independent
experiments. CTL, control. *P < 0.05, **P < 0.01, and ***P < 0.001.
PAR-2 in Pancreatic Cancer ProgressionIn our previous study, signaling pathways induced by
GPCRs, such as the AKT/mammalian target of rapamycin
pathway, promoted the translation of HIF-a protein under
normoxic conditions.16 Herein, we demonstrated that acti-
vated PAR-2 by PAR-2 AP or FVIIa increased the protein
expression of both HIF-1a and HIF-2a in human pancreatic
cancer cells (Figure 2, AeC). We also found that both the
BxPC-3 and AsPC-1 human pancreatic cancer cell lines
expressed TF and PAR-2 mRNA (Figure 1A). Therefore,
PAR-2 signaling certainly increased HIF-a protein expres-
sion in pancreatic cancer cells. Consistent with the results of
our microarray analysis, both TGF-a and VEGF-A mRNA
and protein levels increased after treatment with PAR-2 APThe American Journal of Pathology - ajp.amjpathol.org(Figure 2, DeF). TGF-a and VEGF-A are common target
genes of HIF-1a and HIF-2a. The silencing of HIF-1a and
HIF-2a, or treatmentwith theHIF-a inhibitor, YC-1, depleted
TGF-a protein levels (Figure 3, B and D). However, the
silencing of neither HIF-1a nor HIF-2a attenuated PAR-2
AP-induced VEGF-A production (Figure 3C). We, there-
fore, suggest that the activation of PAR-2 signaling stimulates
TGF-a protein expression through anHIF-1ae andHIF-2ae
dependent pathway.
TGF-a, an EGFR ligand, selectively binds to EGFR and
activates EGFR-mediated signaling pathways, which regulate
cell proliferation, differentiation, cell motility, and survival.23
The up-regulation of TGF-a after HIF activation directly
causes autocrine EGFR signaling.24 In human pancreatic
cancer, the overexpression of TGF-a cooperates with tumor
suppressor, p53, to induce secondary genetic changes25 and
constitutively activates EGFR signaling to produce a
geﬁtinib-effective phenotype.26 Hence, our data suggest that
PAR-2emediated TGF-a expression regulates cross talkwith
EGFR signaling and promotes pancreatic cancer progression.
Much research is focused on the HIF switch. HIFs play
a biological role in the hypoxic tumor microenvironment;
acute hypoxia causes a rapid response and increases HIF-1a
transactivation, thereby promoting angiogenesis to obtain
oxygen. In contrast, chronic hypoxia mediates HIF-2ae
dependent transactivation to remodel blood vessels and
improves cell adaptation.14 The results of this study have
demonstrated that the depletion of HIF-1a by HIF-1a siRNA
enhanced the nuclear expression of HIF-2a, with or without
PAR-2 AP treatment (Figure 3A). We, therefore, speculate
that HIF-2a is an important transcription factor in PAR-
2emediated signaling and that unidentiﬁed mediators regu-
late the interaction between HIF-1a and HIF-2a. HIF-2a is
also known to interact with SP1 and HDAC4 to enhance FVII
gene transcription,27 indicating that the activation and switch
of HIF-2a may alter cellular functions and increase the inci-
dence of cancer-related thrombosis. Both HIF-1a andHIF-2a
up-regulate genes involved in proliferation, angiogenesis, and
metastasis, and are associated with tumor progression in
several types of cancers. We also tested whether activated
PAR-2 could increase the levels of adrenomedullin, GLUT1,
and hexokinase-2 mRNA (Supplemental Figure S1), which
act to regulate tumor progression in various ways.
ILK is a serine/threonine protein kinase that can directly
interact with the cytoplasmic domain of integrins and
possesses kinase activity regulated by cell-matrix interac-
tions.28 TF has the ability to cross talk with b1 integrin,29
which binds with ILK. Indeed, treatment with PAR-2 AP
induced the expression of p-AKT (Ser-473) and p-GSK-3b
(Ser-9), which are downstream substrates of ILK, although
a decrease in ILK levels as a result of siRNA treatment
reduced PAR-2 AP-induced p-AKT (Ser-473) but not
p-GSK-3b (Ser-9) expression (Figure 4C). In the results of
this study, ERK is also not regulated by ILK. A study has
indicated that ERK-primed inhibition of GSK-3b (p-Ser9)
activity has been shown to be regulated by growth factors.30573
Chang et alWe, therefore, suggest that p-GSK-3b (Ser-9) is phosphor-
ylated through the ERK/p90RSk pathway, rather than
through activated ILK. We further demonstrated that the
inhibition of the ILK-AKT pathway by siILK resulted in the
attenuation of HIF-aeinduced TGF-a production, but not
VEGF-A release (Figure 4, D and E). Compared with human
prostate cancer cells,10 our results indicate that the ILK-AKT
pathway directly increases TGF-a production via an HIF-
1ae and HIF-2aedependent pathway in human pancreatic
cancer cells. A previous report has shown that IL-1a
promotes ILK kinase activity, leading to pancreatic cancer
progression and poor patient survival.31 We also found that
the activation of PAR-2 induced the expression of IL-1a and
other related genes, such as those encoding IL-1 receptor
type 1 and toll-like receptor 4, and regulated the NF-kB
pathway (Supplemental Table S1). This increase in IL-1a
expression may, therefore, cause a positive feedback, re-
sulting in enhanced ILK activity and downstream signaling
in pancreatic cancer cells.
Tumor angiogenesis involves multiple processes, in-
cluding interactions between tumor cells and the tumor
microenvironment. Herein, we found that PAR-2 AP
induced the release of VEGF-A, which promotes angio-
genesis, in human pancreatic cancer cells and that this could
be attenuated by the MEK inhibitor, PD98059 (Figure 5).
This is similar to the results obtained for human breast cancer
cells5 and human glioblastoma cells.6 According to our
microarray analysis, the activation of PAR-2 signaling
induced the expression of MAPK1, ETS-1, and c-JUN,
which correlated with increased VEGF-A production. The
proto-oncogene, Ets-1, which is regulated by p-ERK,32 is
known to control the expression of VEGF-A33 and VEGF
receptor 2, and it enhances tumor progression and promotes
ECs to an angiogenic phenotype through their up-regulation.
In this study, PAR-2 AP-treated tumor-conditioned medium
signiﬁcantly enhanced HUVEC proliferation and tube
formation, which could be attenuated by using a conditioned
medium containing the MEK inhibitor, PD98059 (Figure 5,
B and C). MEK, as a direct signal mediator of p-ERK,
therefore, induces angiogenesis through the activation of
PAR-2 and subsequent VEGF-A release from human
pancreatic cancer cells.
Collectively, our results have shown that PAR-2 signaling
has effects on tumor cells and the tumor microenvironment
and that these effects act to promote pancreatic tumor
progression. First, the activation of PAR-2 enhances the
expression of both HIF-1a and HIF-2a, which leads to
increased TGF-a expression via ILK signaling, and it ulti-
mately disposes pancreatic cancer cells to adaptation and
progression. Second, MAPK plays a major role in controlling
PAR-2einduced VEGF-A release and, consequently, an-
giogenesis. In conclusion, our experiments provide evidence
that TF/FVII/PAR-2 signaling plays various roles in the
development of pancreatic cancer, and it may provide an
explanation for the correlation between pancreatic cancer and
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